[Anti-atherosclerotic effects of PPAR gamma ligands]

Shu Wakino1

  • 1Department of Emergency Medicine, School of Medicine, Keio University.

Insights

Peroxisome proliferator-activated receptor gamma (PPAR gamma) ligands show anti-atherosclerosis effects by reducing lesion formation and intimal hyperplasia in studies. These ligands also attenuate intima-media thickness increases in diabetic patients, though long-term impacts require further investigation.

Area of Science:

  • Cardiovascular Research
  • Endocrinology
  • Molecular Biology

Context:

  • Peroxisome proliferator-activated receptor gamma (PPAR gamma), a nuclear receptor, is activated by insulin sensitizers like thiazolidinediones.
  • PPAR gamma is expressed in vascular tissues, influencing endothelial cells, smooth muscle cells, and macrophages.
  • PPAR gamma ligands demonstrate pleiotropic effects on vascular cells.

Purpose:

  • To investigate the role and therapeutic potential of PPAR gamma ligands in the context of atherosclerosis.
  • To summarize the anti-atherosclerotic effects of PPAR gamma ligands observed in preclinical and clinical studies.

Summary:

  • PPAR gamma ligands exhibit significant anti-atherosclerotic properties, attenuating lesion development and intimal hyperplasia in various animal models.
  • In human studies, particularly in diabetic patients, PPAR gamma ligands have been shown to reduce intima-media thickness.
  • The expression of PPAR gamma in key vascular cell types underscores its importance in vascular homeostasis and disease.

Impact:

  • PPAR gamma ligands represent a promising therapeutic strategy for managing and potentially preventing atherosclerosis.
  • Further long-term studies are warranted to fully elucidate the sustained benefits and safety profile of PPAR gamma ligands in atherogenesis.
  • Understanding PPAR gamma's function in vascular cells opens new avenues for targeted therapies against cardiovascular diseases.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
144
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
6.5K
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
2.1K
GPCR Desensitization01:12

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
7.3K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
326
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.1K